Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017477151> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W2017477151 endingPage "31" @default.
- W2017477151 startingPage "27" @default.
- W2017477151 abstract "Sorafenib is considered a standard of care in advanced hepatocellular carcinoma (HCC). Its combination with gemcitabine, a pyrimidine analogue with limited friendly hepatic profile may prove beneficial in advanced HCC. The primary objective was to evaluate the efficacy and safety of a sorafenib and gemcitabine combination in patients with advanced HCC.This was a non-randomized, open-label, single-arm, multi-centric Phase II study conducted in Pakistan where 30 treatment-naive patients aged between 26 and 73 years with Child-Pugh score A or B were treated with sorafenib (400 mg oral) twice daily for 16 weeks along with gemcitabine (1000 mg/m(2) intravenous) administered on day 1 and day 8 of a four-week cycle for 16 weeks.Of the 18 patients (60%) who completed all four cycles of treatment, eight patients had stable disease, two had partial response, and eight had progressive disease. There was no complete response. The most common (≥10% patients) treatment-emergent adverse events were gemcitabine-related thrombocytopenia (40%) followed by sorafenib-related hand-foot skin reaction and anorexia (33% each).The efficacy of sorafenib gemcitabine combination therapy is similar to the sorafenib alone treatment. However, frequent dose adjustments due to gemcitabine-related toxicities, delays, and corrective treatments make this combination therapy unsafe in the treatment of advanced HCC." @default.
- W2017477151 created "2016-06-24" @default.
- W2017477151 creator A5035934048 @default.
- W2017477151 creator A5058370086 @default.
- W2017477151 creator A5067849119 @default.
- W2017477151 creator A5079681264 @default.
- W2017477151 date "2014-03-01" @default.
- W2017477151 modified "2023-10-15" @default.
- W2017477151 title "Efficacy and safety of sorafenib–gemcitabine combination therapy in advanced hepatocellular carcinoma: An open-label Phase II feasibility study" @default.
- W2017477151 cites W1857440086 @default.
- W2017477151 cites W1971837077 @default.
- W2017477151 cites W1988298330 @default.
- W2017477151 cites W1994193851 @default.
- W2017477151 cites W2020830322 @default.
- W2017477151 cites W2046667245 @default.
- W2017477151 cites W2056527566 @default.
- W2017477151 cites W2099774889 @default.
- W2017477151 cites W2106602049 @default.
- W2017477151 cites W2138610774 @default.
- W2017477151 cites W2152746495 @default.
- W2017477151 cites W2155152791 @default.
- W2017477151 doi "https://doi.org/10.1016/j.hemonc.2013.11.003" @default.
- W2017477151 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24333135" @default.
- W2017477151 hasPublicationYear "2014" @default.
- W2017477151 type Work @default.
- W2017477151 sameAs 2017477151 @default.
- W2017477151 citedByCount "11" @default.
- W2017477151 countsByYear W20174771512014 @default.
- W2017477151 countsByYear W20174771512015 @default.
- W2017477151 countsByYear W20174771512016 @default.
- W2017477151 countsByYear W20174771512017 @default.
- W2017477151 countsByYear W20174771512019 @default.
- W2017477151 countsByYear W20174771512020 @default.
- W2017477151 countsByYear W20174771512021 @default.
- W2017477151 countsByYear W20174771512023 @default.
- W2017477151 crossrefType "journal-article" @default.
- W2017477151 hasAuthorship W2017477151A5035934048 @default.
- W2017477151 hasAuthorship W2017477151A5058370086 @default.
- W2017477151 hasAuthorship W2017477151A5067849119 @default.
- W2017477151 hasAuthorship W2017477151A5079681264 @default.
- W2017477151 hasBestOaLocation W20174771511 @default.
- W2017477151 hasConcept C126322002 @default.
- W2017477151 hasConcept C141071460 @default.
- W2017477151 hasConcept C143998085 @default.
- W2017477151 hasConcept C197934379 @default.
- W2017477151 hasConcept C2776694085 @default.
- W2017477151 hasConcept C2776999253 @default.
- W2017477151 hasConcept C2778019345 @default.
- W2017477151 hasConcept C2778654693 @default.
- W2017477151 hasConcept C2778695046 @default.
- W2017477151 hasConcept C2780258809 @default.
- W2017477151 hasConcept C71924100 @default.
- W2017477151 hasConcept C90924648 @default.
- W2017477151 hasConceptScore W2017477151C126322002 @default.
- W2017477151 hasConceptScore W2017477151C141071460 @default.
- W2017477151 hasConceptScore W2017477151C143998085 @default.
- W2017477151 hasConceptScore W2017477151C197934379 @default.
- W2017477151 hasConceptScore W2017477151C2776694085 @default.
- W2017477151 hasConceptScore W2017477151C2776999253 @default.
- W2017477151 hasConceptScore W2017477151C2778019345 @default.
- W2017477151 hasConceptScore W2017477151C2778654693 @default.
- W2017477151 hasConceptScore W2017477151C2778695046 @default.
- W2017477151 hasConceptScore W2017477151C2780258809 @default.
- W2017477151 hasConceptScore W2017477151C71924100 @default.
- W2017477151 hasConceptScore W2017477151C90924648 @default.
- W2017477151 hasIssue "1" @default.
- W2017477151 hasLocation W20174771511 @default.
- W2017477151 hasLocation W20174771512 @default.
- W2017477151 hasLocation W20174771513 @default.
- W2017477151 hasOpenAccess W2017477151 @default.
- W2017477151 hasPrimaryLocation W20174771511 @default.
- W2017477151 hasRelatedWork W1970460092 @default.
- W2017477151 hasRelatedWork W2034139851 @default.
- W2017477151 hasRelatedWork W2087356637 @default.
- W2017477151 hasRelatedWork W2280419820 @default.
- W2017477151 hasRelatedWork W2415536161 @default.
- W2017477151 hasRelatedWork W2769323635 @default.
- W2017477151 hasRelatedWork W3018861914 @default.
- W2017477151 hasRelatedWork W4285206599 @default.
- W2017477151 hasRelatedWork W4361816912 @default.
- W2017477151 hasRelatedWork W4362622788 @default.
- W2017477151 hasVolume "7" @default.
- W2017477151 isParatext "false" @default.
- W2017477151 isRetracted "false" @default.
- W2017477151 magId "2017477151" @default.
- W2017477151 workType "article" @default.